FDA Approves LLY Olumiant for Adolescent Alopecia Areata

Eli Lilly’s (LLY) Olumiant (baricitinib) won FDA approval on September 25 for severe alopecia areata in patients 12 and older, becoming the second oral JAK inhibitor cleared for adolescent hair loss. It joins Pfizer’s LITFULO (ritlecitinib), approved for the same ages in June 2023, rather than opening a new category.

The approval rests on 36-week data from BRAVE-AA-PEDS (NCT05723198), the first large Phase 3 trial built specifically for pediatric severe alopecia areata. The first cohort randomized 257 adolescents one-to-one-to-one to placebo, 4 mg, or 2 mg daily. At baseline, the median Severity of Alopecia Tool (SALT) score was 100, meaning complete scalp hair loss, and patients had lived with the disease for a mean of 6.4 years.

At week 36, 42% of patients on 4 mg and 27% on 2 mg reached a SALT score of 20 or lower, the bar for 80% or more scalp hair coverage, versus 5% on placebo. On the stricter SALT threshold of 10 or lower, the split was 37% and 21% against 2% for placebo. Eyebrow and eyelash regrowth also favored the 4 mg dose. Lilly closed at $1,183.46, essentially unmoved, as investors read the news as a modest label expansion rather than a new franchise.

Baricitinib is an oral JAK1/JAK2 inhibitor discovered by Incyte and licensed to Lilly. It has been prescribed to more than 33,000 US patients since 2017 and was the first systemic treatment approved for adult severe alopecia areata in 2022. The pediatric approval mirrors an April 2026 European Commission authorization for the same adolescent group.

The distinction that matters for dermatologists is selectivity and safety. Baricitinib blocks JAK1 and JAK2; ritlecitinib blocks JAK3 and TEC kinases, and Sun Pharma’s deuruxolitinib, a JAK1/JAK2 inhibitor approved in 2024, is adults-only. All three carry the same JAK-class boxed warning covering serious infections, mortality, malignancy, major cardiovascular events, and blood clots. The recommended dose is 2 mg daily, stepped up to 4 mg for an inadequate response, with 4 mg an option for near-total scalp loss. Patients should not receive live vaccines during treatment.

Severe alopecia areata in adolescence carries an outsized psychosocial burden, and until ritlecitinib’s 2023 approval this age group was managed almost entirely off-label. A second labeled option, with a different JAK target and clean pediatric efficacy data, gives clinicians a genuine choice. Incyte’s povorcitinib remains in development and could add a third oral option later.

What to watch next: how Lilly prices and positions Olumiant against ritlecitinib in the adolescent segment, and whether Incyte’s povorcitinib filings shift the competitive picture over the next year. Read what an sNDA label expansion is or the Lilly approval announcement

What It Means for the Trade

The market read this correctly as a modest label expansion — Lilly was essentially unmoved — but the competitive detail matters more than the headline. Pfizer’s LITFULO has had the adolescent segment to itself since 2023, and the first real competition is also the first efficacy bar: 42% of 4 mg patients at SALT 20 or better versus 5% on placebo is a clean result in a population that started at complete scalp loss. Watch the positioning fight on two fronts: dose strategy (Lilly’s 2 mg start with 4 mg step-up versus ritlecitinib’s single regimen) and the eyebrow and eyelash data, which psychosocially matters more to adolescent patients than scalp coverage percentages. For LLY specifically this is rounding-error revenue next to the metabolic franchise — the stock story is elsewhere — but the approval extends a JAK inhibitor Lilly already knows how to commercialize into a segment with essentially zero labeled competition history until now.

Mechanism and Market Context

The mechanism fight inside the JAK class is about which cytokine pathways you block and which you spare. Baricitinib inhibits JAK1 and JAK2, ritlecitinib JAK3 and TEC — different upstream nodes of the same inflammatory cascade that drives the immune attack on hair follicles, which is why dermatologists now have a genuine second option rather than a clone. Both carry the class boxed warning, and that warning is the commercial ceiling: it keeps oral JAKs positioned after topical steroids and behind injectable biologics in most treatment sequences. The segment is small but structurally under-served — until 2023 adolescent severe alopecia areata was managed almost entirely off-label, and Incyte’s povorcitinib could make it a three-way race within a couple of years.

Risks and What Could Go Wrong

1. The class boxed warning caps first-line use and invites payer step therapy before an oral is covered.
2. LITFULO has a three-year head start with prescribers in this exact age group.
3. A third entrant, povorcitinib, could compress both incumbents’ pricing power.
4. Adolescent adherence to a chronic daily pill is a known weak point in dermatology, and 36-week data says nothing about durability at two years.